3D-QSAR studies and molecular docking on [5-(4-amino-1H-benzoimidazol-2-yl)-furan-2-yl]-phosphonic acid derivatives as fructose-1,6-biphophatase inhibitors

Fructose-1,6-biphophatase has been regarded as a novel therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). 3D-QSAR and docking studies were performed on a series of [5-(4-amino-1H-benzoimidazol-2-yl)-furan-2-yl]-phosphonic acid derivatives as fructose-1,6-biphophatase inhibitors. The CoMFA and CoMSIA models using thirty-seven molecules in the training set gave rcv2 values of 0.614 and 0.598, r2 values of 0.950 and 0.928, respectively. The external validation indicated that our CoMFA and CoMSIA models possessed high predictive powers with r02 values of 0.994 and 0.994, rm2 values of 0.751 and 0.690, respectively. Molecular docking studies revealed that a phosphonic group was essential for binding to the receptor, and some key features were also identified. A set of forty new analogues were designed by utilizing the results revealed in the present study, and were predicted with significantly improved potencies in the developed models. The findings can be quite useful to aid the designing of new fructose-1,6-biphophatase inhibitors with improved biological response.

[1]  Arijit Basu,et al.  Development of CoMFA and CoMSIA models of cytotoxicity data of anti-HIV-1-phenylamino-1H-imidazole derivatives. , 2009, European journal of medicinal chemistry.

[2]  D. Rakus,et al.  Nuclear targeting of FBPase in HL-1 cells is controlled by beta-1 adrenergic receptor-activated Gs protein signaling cascade. , 2009, Biochimica et biophysica acta.

[3]  Muhammad Muddassar,et al.  In silico QSAR studies of anilinoquinolines as EGFR inhibitors , 2010, Journal of molecular modeling.

[4]  M. Erion,et al.  Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors. , 2008, Journal of medicinal chemistry.

[5]  Shu-Shen Liu,et al.  CoMFA and CoMSIA analysis of 2,4-thiazolidinediones derivatives as aldose reductase inhibitors , 2009, Journal of molecular modeling.

[6]  I. McLay,et al.  Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups. , 2009, Journal of medicinal chemistry.

[7]  B. Török,et al.  Novel heteroaromatic organofluorine inhibitors of fructose-1,6-bisphosphatase. , 2009, Journal of medicinal chemistry.

[8]  B. Kuhn,et al.  Sulfonylureido thiazoles as fructose-1,6-bisphosphatase inhibitors for the treatment of type-2 diabetes. , 2010, Bioorganic & medicinal chemistry letters.

[9]  Vishal Prakash Zambre,et al.  Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors , 2010, J. Comput. Aided Mol. Des..

[10]  M. Erion,et al.  Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics. , 2010, Journal of medicinal chemistry.

[11]  Mizuki Takahashi,et al.  Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[12]  E. Kantrowitz,et al.  A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. , 2009, Bioorganic & medicinal chemistry.

[13]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[14]  B. Kuhn,et al.  Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. , 2008, Bioorganic & medicinal chemistry letters.

[15]  Serdar Durdagi,et al.  3D QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics studies of fullerene-based HIV-1 PR inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[16]  S. Durdağı,et al.  Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases. , 2009, European journal of medicinal chemistry.

[17]  P. Lan,et al.  3D-QSAR and Molecular Docking Studies on Fused Pyrazoles as p38α Mitogen-Activated Protein Kinase Inhibitors , 2010, International journal of molecular sciences.

[18]  Jae Yoon Chung,et al.  QM/MM based 3D QSAR models for potent B-Raf inhibitors , 2010, J. Comput. Aided Mol. Des..

[19]  Ruisheng Zhang,et al.  CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase. , 2010, European journal of medicinal chemistry.

[20]  P. Roy,et al.  On Some Aspects of Variable Selection for Partial Least Squares Regression Models , 2008 .

[21]  E. Kantrowitz,et al.  Designing inhibitors against fructose 1,6-bisphosphatase: exploring natural products for novel inhibitor scaffolds. , 2010, European journal of medicinal chemistry.

[22]  Xiao-Yun Lu,et al.  3D‐QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore‐based alignment , 2010, Chemical biology & drug design.

[23]  G. Zeng,et al.  3D QSAR studies on ketoamides of human cathepsin K inhibitors based on two different alignment methods. , 2010, European journal of medicinal chemistry.